%PDF-1.4
%
29 0 obj
<>
endobj
26 0 obj
<>
endobj
65 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-04-13T14:32:24Z
2024-03-28T03:41:33-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T03:41:33-07:00
application/pdf
Heather
2003-68.may
uuid:e493da54-1dd1-11b2-0a00-040a27edca00
uuid:e493da57-1dd1-11b2-0a00-380000000000
endstream
endobj
15 0 obj
<>
endobj
16 0 obj
<>
endobj
30 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 7 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 9 0 R/Type/Page>>
endobj
71 0 obj
[75 0 R]
endobj
72 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.00929 Tw 10 0 0 10 54 598.1616 Tm
[(compared to each other)54.8 (. Lack of consensus was also seen in)]TJ
0.18941 Tw 0 -1.2 TD
(those statements that related to the relative GI and renal)Tj
0.0079 Tw T*
[(toxicity comparing dif)17.7 (ferent COXIB and whether these side)]TJ
0.1629 Tw T*
[(ef)17.7 (fects were class or molecule specific. Respondents also)]TJ
-0.01559 Tw T*
(expressed lack of consensus in their confidence in the use of)Tj
0.29761 Tw T*
(these compounds in patients with cardiovascular and/or)Tj
0.20621 Tw T*
[(renal disease, and also in the elderly)64.8 (. )17.7 (The pharmacoeco-)]TJ
0.021 Tw T*
(nomic value of COXIB over existing traditional antiinflam-)Tj
0.0331 Tw T*
(matory options was of general concern. Finally participants)Tj
-0.0327 Tw T*
(expressed a strong desire for more information as to whether)Tj
0.168 Tw T*
(second generation COXIB are likely to confer a superior)Tj
0.02499 Tw T*
(risk/benefit ratio than those currently available. )Tj
-0.03661 Tw 1.2 -1.2 Td
(This exercise and the results obtained constitute a form of)Tj
0.02499 Tw -1.2 -1.2 Td
(needs assessment for further COXIB information. )Tj
0.1369 Tw 1.2 -1.2 Td
(It is clear from the results that there is still a need for)Tj
0.04469 Tw -1.2 -1.2 Td
(additional information concerning the COXIB that, to date,)Tj
0.08411 Tw T*
(has not been met by the numerous programs sponsored by)Tj
0.009 Tw T*
(professional and industry providers. Many issues relating to)Tj
0.12759 Tw T*
(the clinical utilization of the COXIB appear to have been)Tj
0.2894 Tw T*
(adequately addressed, at least to the satisfaction of the)Tj
0.0359 Tw T*
[(participating rheumatologists in our cohort. However)39.7 (, other)]TJ
0.04469 Tw T*
(practical issues concerning the COXIB obviously still need)Tj
0.00349 Tw T*
(to be addressed, although it is unlikely that answers to these)Tj
0.2092 Tw T*
(will be resolved by any additional reanalysis of existing)Tj
0.3055 Tw T*
[(data. )17.7 (The concept and theoretical value of the COXIB)]TJ
-0.0204 Tw T*
(hypothesis has met with a certain level of acceptance among)Tj
0.22279 Tw T*
(rheumatologists, but important questions still need to be)Tj
0.0836 Tw T*
[(answered. )17.7 (This appears to be particularly true with respect)]TJ
0.02341 Tw T*
(to the potential benefit and risk of COXIB in relation to the)Tj
0.16251 Tw T*
[(degree of COX-2 specificity)64.8 (, and begs the question as to)]TJ
0.06371 Tw T*
(whether the development of new compounds that are more)Tj
0.0016 Tw T*
(highly COX-2 specific would confer greater benefit or pref-)Tj
-0.03 Tw T*
(erential toxicity profile than the current compounds. In addi-)Tj
0.12241 Tw T*
(tion, the development of the second generation COXIB is)Tj
0.162 Tw T*
(likely to raise the question in clinical practice as to their)Tj
0.10201 Tw 26.4 40.8 Td
(preferential profile over the existing COXIB, let alone the)Tj
0.04871 Tw T*
(traditional NSAID. Despite the ongoing controversy on the)Tj
-0.0195 Tw T*
(relative cardiovascular and/or renal toxicity of the 2 existing)Tj
0.0089 Tw T*
(COXIB, it is likely that concerns about these issues will not)Tj
0.01691 Tc 0.358 Tw T*
(be allayed until the results of more focused studies)Tj
-0.00011 Tc 0.02499 Tw T*
(addressing these specific questions become available. )Tj
0.25349 Tw 1.2 -1.2 Td
(Areas of potential interest in the future are likely to)Tj
0.0199 Tc 0.3933 Tw -1.2 -1.2 Td
(revolve around risk stratification, pharmacoeconomic)Tj
-0.00011 Tc 0.2601 Tw T*
(benefit, and the use of newer compounds in subsets of)Tj
0.17979 Tw T*
(patients including the elderly and those with cardio/renal)Tj
0 Tw T*
(comorbidities. )Tj
0.12981 Tw 1.2 -1.2 Td
(Is there anything else we could possibly need to know)Tj
0.10249 Tw -1.2 -1.2 Td
[(about the COXIB? )36.8 (Y)99.8 (es, but in the future our deliberations)]TJ
0.1508 Tw T*
(need to address the more specific, practical concerns that)Tj
0.0777 Tw T*
(have been raised and not adequately addressed in previous)Tj
0.07719 Tw T*
[(educational programs. )17.7 (These must be resolved if we are to)]TJ
0.19611 Tw T*
(finally place COX-2 selective antiinflammatories in their)Tj
0.28951 Tw T*
(appropriate therapeutic role. If the issue of the COX-2)Tj
0.2282 Tw T*
(specific antiinflammatories is not heady enough, COX-3)Tj
0.02499 Tw T*
(can only be just around the corner!)Tj
/T1_2 1 Tf
0 Tw 9.8 -2.4 Td
[(P)74 (AUL)-220.2 (DA)128.8 (VIS, )]TJ
/T1_1 1 Tf
0 Tc 0.0249 Tw 6 0 0 6 479.7447 346.1616 Tm
[(MB, ChB, FRCP)110.8 (, FRCPC,)]TJ
-0.00011 Tc 8 0 0 8 416 336.1616 Tm
(Professor of Medicine, )Tj
0 -1.25 TD
(562 Heritage Medical Research Centre, )Tj
T*
[(University of )54.8 (Alberta,)]TJ
T*
[(Edmonton, Canada, )17.7 (T6C 2S2;)]TJ
/T1_2 1 Tf
0 Tw 10 0 0 10 416 296.1616 Tm
[(ANGELA)-220.2 (JUBY)91.7 (,)]TJ
/T1_1 1 Tf
0.02499 Tw 6 0 0 6 491.417 296.1616 Tm
(MB, ChB, Cert. Geriatrics,)Tj
8 0 0 8 416 286.1616 Tm
(Associate Professor of Medicine,)Tj
T*
[(University of )54.8 (Alberta;)]TJ
/T1_2 1 Tf
0 Tw 10 0 0 10 416 264.1616 Tm
[(SHERR)34.8 (Y)-238.2 (ROBER)34.8 (TSON, )]TJ
/T1_1 1 Tf
6 0 0 6 527.3813 264.1616 Tm
(BSc,)Tj
0.02499 Tw 8 0 0 8 416 254.1616 Tm
(Health Education Manager;)Tj
/T1_2 1 Tf
10 0 0 10 416 242.1616 Tm
[(NA)73.9 (THALIE RICHARD,)]TJ
/T1_1 1 Tf
0 Tw 6 0 0 6 524.3589 242.1616 Tm
(BSc,)Tj
0.02499 Tw 8 0 0 8 416 232.1616 Tm
[(Health Education Manager)39.7 (,)]TJ
T*
(Merck Frosst Canada Ltd.,)Tj
T*
(Kirkland, Canada.)Tj
/T1_3 1 Tf
-12.25 -3 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. Davis.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:5)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(848)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_3 1 Tf
0.02499 Tw 8 0 0 8 55 714.5293 Tm
[(T)91.9 (able 1. )]TJ
/T1_1 1 Tf
-0.00011 Tc 3.7608 0 Td
(Concordant and discordant issues regarding COXIB among surveyed Canadian\
Rheumatologists.)Tj
0 Tw -3.7608 -2.5 Td
[(CONCORDANCE)-22289.7 (DISCORDANCE)]TJ
0.02499 Tw 0 -2.5 TD
[(Mode of action of COXIB)-19247.8 (The degree of COX-2 specificity vs toxicity and ef)17.7 (ficacy)]TJ
0 -1.25 TD
[(Analgesic/antiinflammatory benefits vs traditional NSAID)-6364.3 (Head to head comparison of COXIB with respect to ef)17.7 (ficacy and safety)]TJ
T*
[(Ef)17.7 (ficacy in RA)-220.2 (and OA)-220.2 (vs traditional NSAID)-11609.6 (Overall cardiovascular and renal safety of COXIB)]TJ
T*
[(Therapeutic role of COXIB in OA)-220.2 (and RA)-12703.1 (Pharmacoeconomic benefits of COXIB vs NSAID)]TJ
T*
[(Patient risk stratification; safety vs traditional NSAID)-8202.5 (Safety/ef)17.7 (ficacy of second generation COXIB)]TJ
ET
55 709 m
559 709 l
55 689 m
560 689 l
54 627 m
558 627 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
9 0 obj
<>stream
8;Z\7>7Q9>%*ST&R-RF2qH3'Z9dp1AqL_L=3OT$<0J=ui$:Mh>rQ',nFki8&S3:dg
SH:&m96FI/-u:*9:lhhX$-A`9GM&"_pPG\O4#(T'e-YS-Z;E$B-n=l
Lk=ODl*pNTdOoW=:fXD.>=(oq:%cTZCFYbgDXpmE;KY9Z0Ci4))qlH3CNa0$;up>p`Xq9,i)98'jc/"op9XO&qfjHL)JGbI,d0IEnh!k=]@c
-Ws8F6Qb?.>ZVH&1$I./_a`nlI4V90:"OVr2o2>Ki_2^QL[X:2QRO8uDB#,peM]a"
@B6,f.[L[s\Rm$,_/L91+(JR>oOOePnd
endstream
endobj
13 0 obj
[/Indexed/DeviceRGB 255 12 0 R]
endobj
12 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
60 0 obj
<>
endobj
32 0 obj
<>
endobj
4 0 obj
<>
endobj
35 0 obj
<>
endobj
55 0 obj
<>
endobj
70 0 obj
<>
endobj
33 0 obj
<>
endobj
42 0 obj
<>stream
HS{PSwpo[HGEGyR( "@B!$
pP)(⳾]N2?vvvv̙ߜ99ᘻUёkHbż5,ɖUct7֗þ0!69wgEw2$;mUYGso2hQ8 00(DK3-:/~镩1^P
zMsMCE$us0ҐQ8R~zj9rg1a/N͔CnjCvs}Ogu#61k{k
t#u;T
pGDϩCmG*Ѻ,Mq/zEyJkNэRY*)_8x_m+˵>ڭ0qͧ#BXzI3e%v-A߰K.eԸh|1QeS܌ȣF<%m xl$b#)"a{rg ,|¢C9fC!֕Jʳ-n,P@(:X] hzm}o#:},.ҥhzSѵ~[!qb9qd8UAisZg㵡pKw%|BeHU;7ƶUiGĬq>t5f~~Eey^4e81z4BEF(ES[Em/WzkX6næ_Iv۵ɭkyEc1~/3x@
Kbe)gקË|&o%Xog=93w'F(4f7^f붉F#TfiQg[DAB6օ〧ӟRs"$""95R ?+j8Ww$U{B̻;jZ*`aɅzfQW"41;xoW~`O
,"ټA?Pީ`c "
d qB4ۉ&I&Yeĸz۬lwHʘOwMgT74 :.umK崩C kYYe,'$VXR`NѸYݭ̕?4nhq)ʄ%'AsQHGrǐIm"ܷtQ4[*[VaىVWmT]K}-c=]ەݝY'd#E`S%þAsuTHȧC8F"q;iAE.^+\lt w_Id#!O`k:jNKȃzŞt!Oj:XTm"䑕S%92d(--(MWhT;,=6VP *P<^k.)]e'X!()O8)jm6
˽3ꍅ"7~dið+_Ӊ2.-0Fjb٦joHl61L4Fls}17p&* 'Y]Ѫj\sڥ[&r#hmn7!-Ɩh<< /`[H< y@@HQ^|+MAV*}qv{ [=>y.`gR~/_%ͩZa
̤ik/xbO$ʄJnwB]7|bW*v+삳ӾNکju